DrugsControl Media Services
DrugsControl.org

News Detail

Oral Semaglutide shows cardio benefits in certain diabetes patients (22-10-2024)

Bagsværd, Denmark, 21 Oct 2024: As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.

 

Oral semaglutide, sold as Ryb......
View Details

Source : Fierce Pharma
Novo Nordisk cardiovascular outcomes Rybelsus GLP-1 semaglutide clinical trial data Clinical Data Fierce Pharma Homepage Pharma

Related News